"The company has received 180 days marketing exclusivity," Sun Pharma said in a statement, adding that approval is for multiple doses of strengths of 37.5 mg (base), 75 mg (base) and 150 mg (base).
These tablets are equivalent to Osmotica's Venlafaxine hydrochloride extended release tablets. Osmotica, a global pharmaceutical company specialises in drug delivery technologies and neuro based therapies.
Extended release tablets use a mechanism by which the tablets dissolve slowly and release a drug over time. They are taken less frequently and keep steadier levels of drug in the blood stream.
The shares of the company were trading at Rs 1,795.20 at the Bombay Stock Exchange in morning trade, up by 1.65 per cent over the previous close.